Article Text

Download PDFPDF
Severe adverse reactions are rare with infusions of infliximab in a community setting

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Competing interests YY has been a consultant or speaker for BMS, Celgene, Centocor, Genentech, Merck, Pfizer, Roche and UCB.